JBCHEPHARM

JB Chemicals & Pharmaceuticals Limited

Branded pharmaceutical company with formulations and CDMO business

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

Ask AI

Key metrics

Price as of 2026-07-16

Stock price
₹2408.90
Market cap
38,687 Cr
Stock P/E
54.5
P/B
9.30
Dividend yield
0.8%
ROE (FY26)
17.1%
ROCE (FY26)
23.0%
Operating margin (FY26)
22.3%
OCF / EBITDA (FY26)
63.6%
OCF / EBITDA (3Y)
79.3%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

JB Pharma (JB Chemicals & Pharmaceuticals) sells branded medicines in India, sells formulations internationally, and makes products for other companies as a contract development and manufacturing (CDMO) business; Torrent Pharma took control of it in January 2026.

Company snapshot

19thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Net margin of 17.1% — the business keeps a healthy share of every rupee it earns.
2 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricJun 2023Sept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Sales896 Cr882 Cr845 Cr862 Cr1,004 Cr1,001 Cr963 Cr949 Cr1,094 Cr1,085 Cr1,065 Cr904 Cr
Operating expenses (approx.)664 Cr638 Cr621 Cr664 Cr724 Cr730 Cr709 Cr723 Cr793 Cr775 Cr769 Cr703 Cr
EBITDA232 Cr244 Cr223 Cr198 Cr280 Cr271 Cr255 Cr226 Cr301 Cr310 Cr296 Cr201 Cr
OPM %25.9%27.6%26.4%23.0%27.9%27.0%26.4%23.8%27.5%28.5%27.8%22.2%
Other income6 Cr8 Cr7 Cr17 Cr6 Cr10 Cr8 Cr14 Cr15 Cr15 Cr18 Cr12 Cr
Interest12 Cr10 Cr12 Cr9 Cr6 Cr2 Cr3 Cr1 Cr1 Cr1 Cr2 Cr1 Cr
Depreciation31 Cr32 Cr34 Cr41 Cr41 Cr42 Cr42 Cr46 Cr43 Cr44 Cr45 Cr50 Cr
Profit before tax194 Cr209 Cr184 Cr165 Cr240 Cr237 Cr218 Cr193 Cr272 Cr279 Cr267 Cr135 Cr
Tax %26.8%27.8%27.4%23.4%26.3%26.2%25.5%24.5%25.5%25.6%25.8%24.7%
Net profit142 Cr151 Cr134 Cr126 Cr177 Cr175 Cr162 Cr146 Cr202 Cr208 Cr198 Cr101 Cr
EPS (₹)₹18.39₹9.72₹8.62₹8.22₹11.39₹11.24₹10.46₹9.36₹12.99₹13.29₹12.63₹6.35

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,368 Cr1,414 Cr1,643 Cr1,775 Cr2,043 Cr2,424 Cr3,149 Cr3,484 Cr3,918 Cr4,148 CrSign in free for the trailing twelve months
Operating expenses (approx.)1,136 Cr1,196 Cr1,338 Cr1,397 Cr1,482 Cr1,881 Cr2,454 Cr2,587 Cr2,886 Cr3,040 CrSign in free for the trailing twelve months
EBITDA232 Cr218 Cr305 Cr378 Cr560 Cr543 Cr696 Cr897 Cr1,032 Cr1,107 CrSign in free for the trailing twelve months
OPM %17.0%15.4%18.6%21.3%27.4%22.4%22.1%25.7%26.3%26.7%Sign in free for the trailing twelve months
Other income50 Cr37 Cr41 Cr51 Cr112 Cr39 Cr10 Cr37 Cr38 Cr60 CrSign in free for the trailing twelve months
Interest5 Cr3 Cr4 Cr3 Cr7 Cr5 Cr36 Cr44 Cr12 Cr6 CrSign in free for the trailing twelve months
Depreciation47 Cr57 Cr56 Cr66 Cr69 Cr73 Cr114 Cr138 Cr171 Cr183 CrSign in free for the trailing twelve months
Profit before tax230 Cr194 Cr287 Cr349 Cr597 Cr505 Cr555 Cr752 Cr887 Cr952 CrSign in free for the trailing twelve months
Tax %19.8%28.5%32.4%21.9%24.9%23.5%26.2%26.5%25.7%25.5%Sign in free for the trailing twelve months
Net profit184 Cr139 Cr194 Cr272 Cr449 Cr386 Cr410 Cr553 Cr660 Cr709 CrSign in free for the trailing twelve months
EPS (₹)₹21.70₹16.52₹23.54₹34.20₹57.96₹49.86₹53.00₹35.66₹42.45₹45.16Sign in free for the trailing twelve months
Dividend payout %————-16.3%33.0%31.1%28.4%35.9%44.2%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital17 Cr17 Cr16 Cr15 Cr15 Cr15 Cr15 Cr16 Cr16 Cr16 Cr
Reserves1,347 Cr1,425 Cr1,464 Cr1,420 Cr1,794 Cr2,119 Cr2,465 Cr2,908 Cr3,418 Cr4,143 Cr
Borrowings49 Cr29 Cr26 Cr32 Cr33 Cr26 Cr548 Cr357 Cr14 Cr—
Other liabilities259 Cr291 Cr282 Cr344 Cr392 Cr442 Cr525 Cr714 Cr827 Cr809 Cr
Total liabilities1,674 Cr1,765 Cr1,791 Cr1,814 Cr2,238 Cr2,607 Cr3,554 Cr3,994 Cr4,274 Cr4,969 Cr
Fixed assets (net)597 Cr564 Cr544 Cr568 Cr544 Cr519 Cr532 Cr572 Cr610 Cr612 Cr
CWIP4 Cr17 Cr15 Cr16 Cr26 Cr14 Cr44 Cr63 Cr47 Cr61 Cr
Investments411 Cr434 Cr457 Cr403 Cr678 Cr13 Cr206 Cr388 Cr345 Cr765 Cr
Loans & advances——1 Cr4 Cr2 Cr1 Cr1 Cr0.70 Cr0.55 Cr0.54 Cr
Inventories200 Cr214 Cr244 Cr275 Cr347 Cr410 Cr430 Cr503 Cr529 Cr683 Cr
Trade receivables266 Cr301 Cr309 Cr345 Cr389 Cr556 Cr576 Cr687 Cr815 Cr781 Cr
Cash & bank13 Cr30 Cr35 Cr29 Cr29 Cr57 Cr77 Cr88 Cr115 Cr110 Cr
Other assets183 Cr206 Cr185 Cr173 Cr223 Cr1,038 Cr1,687 Cr1,693 Cr1,812 Cr1,956 Cr
Total assets1,674 Cr1,765 Cr1,791 Cr1,814 Cr2,238 Cr2,607 Cr3,554 Cr3,994 Cr4,274 Cr4,969 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity201 Cr123 Cr193 Cr275 Cr315 Cr170 Cr626 Cr801 Cr902 Cr704 Cr
Cash from investing-45 Cr-21 Cr-27 Cr24 Cr-231 Cr2 Cr-962 Cr-404 Cr-296 Cr-586 Cr
Cash from financing-184 Cr-60 Cr-155 Cr-306 Cr87 Cr-138 Cr357 Cr-385 Cr-580 Cr-123 Cr
Net cash flow-28 Cr43 Cr11 Cr-6 Cr172 Cr34 Cr20 Cr11 Cr27 Cr-5 Cr
Free cash flow (OCF − Capex)45 Cr86 Cr145 Cr202 Cr267 Cr-537 Cr-139 Cr539 Cr782 Cr704 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %16.6%13.4%19.3%23.9%32.7%23.6%19.5%24.3%26.1%23.0%
ROE %13.5%9.6%13.1%18.9%24.7%18.0%16.5%18.9%19.2%17.1%
Debtor days71776971698367727669
Inventory days198201196222233248200225235273
Days payable9810466100125136111159182156
Cash conversion cycle171175198193177196156137128185
OCF / EBITDA %86.6%56.5%63.2%72.9%56.2%31.3%89.9%89.3%87.5%63.6%
OCF / EBITDA % (3 years)——68.5%65.7%63.0%51.3%61.7%74.7%88.7%79.3%
Debt / equity0.040.020.020.020.020.010.220.120.0040—
Current ratio2.833.814.323.434.503.322.802.153.064.98
Net debt / EBITDA0.15—-0.030.00800.0071-0.060.680.30-0.10-0.10